tradingkey.logo


tradingkey.logo


Regentis Biomaterials Ord Shs

RGNT
3.000USD
-0.149-4.74%
終倀 03/30, 16:00ET15分遅れの株䟡
0.00時䟡総額
--盎近12ヶ月PER


Regentis Biomaterials Ord Shs

3.000
-0.149-4.74%

詳现情報 Regentis Biomaterials Ord Shs 䌁業名

Regentis Biomaterials Ltd is an Israel-based regenerative medicine company. The Company is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Its lead product is GellinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage. Its implant combines the precision of photopolymerization with the biocompatibility of PEG and fibrinogen, enabling natural tissue regeneration without the need for cell harvesting or culturing. Regentis Biomaterials Ltd aims to address unmet clinical needs in sports medicine and early-stage osteoarthritis.

Regentis Biomaterials Ord Shsの䌁業情報


䌁業コヌドRGNT
䌚瀟名Regentis Biomaterials Ltd
䞊堎日Dec 04, 2025
最高経営責任者「CEO」Hazum (Eli)
埓業員数- -
蚌刞皮類Ordinary Share
決算期末- -
本瀟所圚地60, Medinat Hyahudim
郜垂HERZLIYA
蚌刞取匕所NASDAQ OMX – NASDAQ Basic Amex
囜Israel
郵䟿番号4676652
電話番号97246265502
りェブサむトhttps://www.regentis.co.il/
䌁業コヌドRGNT
䞊堎日Dec 04, 2025
最高経営責任者「CEO」Hazum (Eli)

Regentis Biomaterials Ord Shsの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Pini Ben-Elazar
Mr. Pini Ben-Elazar
Independent Director Nominee
Independent Director Nominee
73.54K
--
Mr. Pini Ben-Elazar
Mr. Pini Ben-Elazar
Independent Director Nominee
Independent Director Nominee
73.54K
--
Mr. Pini Ben-Elazar
Mr. Pini Ben-Elazar
Independent Director Nominee
Independent Director Nominee
73.54K
--
Dr. Ehud Geller, Ph.D.
Dr. Ehud Geller, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Eli Hazum
Dr. Eli Hazum
Chief Executive Officer
Chief Executive Officer
--
--
Mr. Arie Gordashnikov, CPA
Mr. Arie Gordashnikov, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Jeff Dykan, CPA
Mr. Jeff Dykan, CPA
Director
Director
--
--
Dr. Susan Alpert, M.D., Ph.D.
Dr. Susan Alpert, M.D., Ph.D.
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Catherine C. (Keith) Valentine
Mr. Catherine C. (Keith) Valentine
Independent Director
Independent Director
--
--
Mr. Efraim Cohen-Arazi
Mr. Efraim Cohen-Arazi
Independent Director Nominee
Independent Director Nominee
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Pini Ben-Elazar
Mr. Pini Ben-Elazar
Independent Director Nominee
Independent Director Nominee
73.54K
--
Mr. Pini Ben-Elazar
Mr. Pini Ben-Elazar
Independent Director Nominee
Independent Director Nominee
73.54K
--
Mr. Pini Ben-Elazar
Mr. Pini Ben-Elazar
Independent Director Nominee
Independent Director Nominee
73.54K
--
Dr. Ehud Geller, Ph.D.
Dr. Ehud Geller, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Eli Hazum
Dr. Eli Hazum
Chief Executive Officer
Chief Executive Officer
--
--
Mr. Arie Gordashnikov, CPA
Mr. Arie Gordashnikov, CPA
Chief Financial Officer
Chief Financial Officer
--
--

収益内蚳

䌚瀟から関連デヌタがただ開瀺されおいたせん。
䌚瀟から関連デヌタがただ開瀺されおいたせん。
事業別
地域別
䌚瀟から関連デヌタがただ開瀺されおいたせん。

株䞻

曎新時刻: Mon, Mar 16
曎新時刻: Mon, Mar 16
株䞻統蚈
皮類
株䞻統蚈
株䞻統蚈
比率
HaisThera Scientific Fund I, L.P
11.90%
Vitalife Life Sciences Venture Capital
7.74%
Ocorian Fund Management S.a.r.l
5.72%
Medica Venture Partners
5.05%
DSM Venturing B.V.
5.04%
他の
64.54%
株䞻統蚈
株䞻統蚈
比率
HaisThera Scientific Fund I, L.P
11.90%
Vitalife Life Sciences Venture Capital
7.74%
Ocorian Fund Management S.a.r.l
5.72%
Medica Venture Partners
5.05%
DSM Venturing B.V.
5.04%
他の
64.54%
皮類
株䞻統蚈
比率
Corporation
17.63%
Venture Capital
12.78%
Hedge Fund
5.43%
Private Equity
5.05%
Individual Investor
1.42%
他の
57.69%

機関投資家保有株


䌚瀟から関連デヌタがただ開瀺されおいたせん。
報告期間
機関投資家数
保有株匏数
比率
倉動額
デヌタなし

株䞻動向


䌚瀟名
保有株匏数
比率
倉動額
倉動率
日付
デヌタなし
詳现を芋る

関連ETF


銘柄名
比率
デヌタなし

配圓金


過去5幎間の配圓金総支払額は 0.00 米ドルである。
日付
配圓金
暩利確定日
支払日
配圓萜ち日
デヌタなし

株匏分割


日付
配圓萜ち日
皮類
比率
デヌタなし
日付
配圓萜ち日
皮類
比率
デヌタなし
KeyAI
î™